1 |
Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, et al. : Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134 : 705-714, 2017
DOI
|
2 |
Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, et al. : C11orf95-RELA fusions drive oncogenic signalling in ependymoma. Nature 506 : 451-455, 2014
DOI
|
3 |
Paulino AC : The local field in infratentorial ependymoma: does the entire posterior fossa need to be treated? Int J Radiat Oncol Biol Phys 49 : 757-761, 2001
DOI
|
4 |
Paulino AC, Wen BC : The significance of radiotherapy treatment duration in intracranial ependymoma. Int J Radiat Oncol Biol Phys 47 : 585-589, 2000
DOI
|
5 |
Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, et al. : Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol 34 : 2468-2477, 2016
DOI
|
6 |
Ruda R, Bosa C, Magistrello M, Franchino F, Pellerino A, Fiano V, et al. : Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol 18 : 261-268, 2016
DOI
|
7 |
Venkatramani R, Dhall G, Patel M, Grimm J, Hawkins C, McComb G, et al. : Supratentorial ependymoma in children: to observe or to treat following gross total resection? Pediatr Blood Cancer 58 : 380-383, 2012
DOI
|
8 |
Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al. : Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20 : 143-157, 2011
DOI
|
9 |
Venkatramani R, Ji L, Lasky J, Haley K, Judkins A, Zhou S, et al. : Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial. J Neurooncol 113 : 285-291, 2013
DOI
|
10 |
Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, et al. : Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol 17 : 440-447, 2015
DOI
|
11 |
Chamberlain MC, Johnston SK : Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer 115 : 4775-4782, 2009
DOI
|
12 |
Aizer AA, Ancukiewicz M, Nguyen PL, Macdonald SM, Yock TI, Tarbell NJ, et al. : Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol 115 : 411-419, 2013
DOI
|
13 |
Archer TC, Pomeroy SL : Posterior fossa ependymomas: a tale of two subtypes. Cancer Cell 20 : 133-134, 2011
DOI
|
14 |
Benesch M, Weber-Mzell D, Gerber NU, von Hoff K, Deinlein F, Krauss J, et al. : Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. J Neurosurg Pediatr 6 : 137-144, 2010
DOI
|
15 |
Brandes AA, Cavallo G, Reni M, Tosoni A, Nicolardi L, Scopece L, et al. : A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer 104 : 143-148, 2005
DOI
|
16 |
Chai YH, Jung S, Lee JK, Kim IY, Jang WY, Moon KS, et al. : Ependymomas: prognostic factors and outcome analysis in a retrospective series of 33 patients. Brain Tumor Res Treat 5 : 70-76, 2017
DOI
|
17 |
Gojo J, Lotsch D, Spiegl-Kreinecker S, Pajtler KW, Neumayer K, Korbel P, et al. : Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro Oncol 19 : 1183-1194, 2017
DOI
|
18 |
DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, et al. : An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol 123 : 85-91, 2015
DOI
|
19 |
Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, et al. : Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10 : 7, 2011
DOI
|
20 |
Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, et al. : A phase II study of lapatinib and dose dense temozolomide (TMZ) for adults with recurrent ependymoma: a CERN clinical trial. Neuro Oncol 16(suppl_5) : v13, 2014
|
21 |
Gornet MK, Buckner JC, Marks RS, Scheithauer BW, Erickson BJ : Chemotherapy for advanced CNS ependymoma. J Neurooncol 45 : 61-67, 1999
DOI
|
22 |
Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, et al. : Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28 : 3182-3190, 2010
DOI
|
23 |
Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, et al. : Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 : 445-450, 2014
DOI
|
24 |
Leeper H, Felicella MM, Walbert T : Recent advances in the classification and treatment of ependymomas. Curr Treat Options Oncol 18 : 55, 2017
DOI
|
25 |
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. : The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131 : 803-820, 2016
DOI
|
26 |
Mack SC, Taylor MD : Put away your microscopes: the ependymoma molecular era has begun. Curr Opin Oncol 29 : 443-447, 2017
DOI
|
27 |
Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leonard JR, et al. : Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 61 : 387-391, 2005
DOI
|
28 |
Massimino M, Solero CL, Garre ML, Biassoni V, Cama A, Genitori L, et al. : Second-look surgery for ependymoma: the Italian experience. J Neurosurg Pediatr 8 : 246-250, 2011
DOI
|
29 |
Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, et al. : Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol 12 : 976-984, 2010
DOI
|
30 |
Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA : Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 10 : 258-266, 2009
DOI
|
31 |
Modena P, Buttarelli FR, Miceli R, Piccinin E, Baldi C, Antonelli M, et al. : Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro Oncol 14 : 1346-1356, 2012
DOI
|
32 |
Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, et al. : Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27 : 728-743, 2015
DOI
|
33 |
Nakamura T, Fukuoka K, Ikeda J, Yoshitomi M, Udaka N, Tanoshima R, et al. : Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma. Brain Tumor Pathol 34 : 160-164, 2017
DOI
|
34 |
Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, et al. : The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133 : 5-12, 2017
DOI
|
35 |
Pajtler KW, Pfister SM, Kool M : Molecular dissection of ependymomas. Oncoscience 2 : 827-828, 2015
|